Improving Report of the ADAURA Trial by Distinguishing Treatment-Related Adverse Events From Treatment-Emergent Adverse Events and Assessing Independence of Censoring in Final Disease-Free Survival Analyses

Herbst et al 1 present the final disease-free survival (DFS) analysis of the phase III ADAURA (ClinicalTrials.govidentifier: NCT02511106) trial which shows a meaningful DFS benefit with adjuvant osimertinib over placebo in epidermal growth factor receptor-mutated stage IB-IIIA non-small-cell lung cancer (NSCLC) after complete tumor resection (hazard ratio [HR], 0.27 [95% CI, 0.21 to 0.31]).The authors also report the long-term profile of safety with osimertinib versus placebo.Although the final data of DFS and adverse events are important, we believe that there are few crucial concerns that necessitate further explorations.